At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Closed 11-15 16:00:00 EST
34.17
-3.52
-9.34%
盘后34.17
+0.000.00%
19:30 EST
High37.76
Low33.92
Vol1.08M
Open37.75
D1 Closing37.69
Amplitude10.19%
Mkt Cap1.95B
Tradable Cap1.75B
Total Shares57.20M
T/O37.48M
T/O Rate2.11%
Tradable Shares51.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Stock Track | Structure Therapeutics Plummets 8.94% as Trump's HHS Pick Could Threaten Weight-Loss Drug Prospects
Structure Therapeutics Announces First Patients Dosed in Phase 2B Access Clinical Study Evaluating Oral Small Molecule Glp-1 Receptor Agonist, Gsbr-1290, for Obesity
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.